Skip to main content
. 2022 Mar 10;9:157–170. doi: 10.2147/JHC.S353956

Figure 3.

Figure 3

Kaplan–Meier curves for progression-free survival (PFS) of patients with advanced hepatocellular carcinoma who received regorafenib combined with sintilimab (rego-sintilimab) (median PFS, 5.6 months; 95% CI, 4.2–7.0) or regorafenib (median PFS, 4.0 months; 95% CI, 2.5–5.5; P = 0.045) in a second-line setting.

Abbreviation: CI, confidence interval.